SAN FRANCISCO (MarketWatch) -- GlaxoSmithKline plc said Monday the supplemental new drug application for its anticoagulant drug candidate Arixtra has been accepted for priority review by the Food and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results